Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial.

ABSTRACT:

Objective

To preliminarily assess the safety and efficacy of transdermal nicotine therapy on cognitive performance and clinical status in subjects with mild cognitive impairment (MCI).

Methods

Nonsmoking subjects with amnestic MCI were randomized to transdermal nicotine (15 mg per day or placebo) for 6 months. Primary outcome variables were attentional improvement assessed with Connors Continuous Performance Test (CPT), clinical improvement as measured by clinical global impression, and safety measures. Secondary measures included computerized cognitive testing and patient and observer ratings.

Results

Of 74 subjects enrolled, 39 were randomized to nicotine and 35 to placebo. 67 subjects completed (34 nicotine, 33 placebo). The primary cognitive outcome measure (CPT)

SUBMITTER: Newhouse P 

PROVIDER: S-EPMC3466669 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature